| Capdevila, Jaume |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
LEVEL, NCT05918302: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. |
|
|
| Recruiting | 3 | 120 | Europe | 177Lu-edotreotide, Everolimus | Grupo Espanol de Tumores Neuroendocrinos, ITM Oncologics GmbH, MFAR | Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms | 03/28 | 07/28 | | |
| Completed | 2 | 126 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675,206 | Grupo Espanol de Tumores Neuroendocrinos | Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | 11/19 | 05/22 | | |
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial |
|
|
| Terminated | 2 | 79 | Europe | Durvalumab, MEDI4736, Tremelimumab | Grupo Espanol de Tumores Neuroendocrinos, MFAR | Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 78 | Europe, US | Surufatinib, HMPL-012, sulfatinib | Hutchmed | Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET | 09/24 | 09/24 | | |
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study |
|
|
| Active, not recruiting | 2 | 93 | Europe | Cabozantinib 40 mg, Atezolizumab 1200 mg | Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG | Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma | 12/23 | 03/24 | | |
| Recruiting | 2 | 42 | Europe | Sacituzumab govitecan, Trodelvy | Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences | Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | 12/27 | 12/27 | | |
DUREC, NCT04293419: Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 58 | Europe | Durvalumab (MEDI4736) | Grupo Espanol Multidisciplinario del Cancer Digestivo, AstraZeneca, Vall d'Hebron Institute of Oncology (VHIO) | Rectal Cancer | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 41 | Europe | Cabozantinib | Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR | Differentiated Thyroid Cancer | 06/25 | 06/25 | | |
| Recruiting | 2 | 45 | Europe | Atezolizumab plus Tiraglolumab | Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche | Squamous Cell Carcinoma of the Anal Canal | 06/27 | 06/28 | | |
| Terminated | 1/2 | 70 | Europe, US | EO2401, Nivolumab | Enterome | Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma | 05/24 | 10/24 | | |
| Recruiting | N/A | 20 | Europe | | Grupo Espanol de Tumores Neuroendocrinos | Thyroid Cancer | 12/25 | 12/25 | | |
| Pavel, Marianne |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
| Active, not recruiting | 2 | 78 | Europe, US | Surufatinib, HMPL-012, sulfatinib | Hutchmed | Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET | 09/24 | 09/24 | | |
| Active, not recruiting | 2 | 45 | Europe | Cabozantinib | Karsten Gavenis | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 09/24 | 10/24 | | |
| Herrmann, Ken |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
| Recruiting | 3 | 148 | Europe | [68Ga]Ga-PentixaFor, [68Ga]Ga-PTF, [18F]Fluorodeoxyglucose, [18F]FDG | Pentixapharm AG, Pivotal S.L. | Marginal Zone Lymphoma | 06/25 | 06/25 | | |
MI-CISDIR, NCT06540872: Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer |
|
|
| Not yet recruiting | 2 | 30 | Europe | [68Ga]Ga-FAPI-46, [68Ga]FAPI-46 | Universität Münster | Carcinoma, Intraductal, Noninfiltrating | 10/26 | 10/26 | | |
| Recruiting | 2 | 50 | Europe | Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca | Intrahepatic Cholangiocarcinoma | 12/25 | 12/25 | | |
| Essler, Markus |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
